CasInvent

CasInvent Pharma

This company develops small molecule inhibitors targeting casein kinase 1 enzymes to treat patients with treatment-resistant cancers such as acute myeloid leukaemia and melanoma.

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.

Type6 Therapeutics

This deep-tech company develops kinase inhibitors for cancer treatment, intercepting enzymes in their inactive states to address drug resistance for patients with aggressive tumours.

THERAtRAME

The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.

Flindr Therapeutics

This company develops small molecule inhibitors for the precision treatment of cancer patients with specific tumor and host factors.

Flindr

The company develops small molecule inhibitors for precision oncology treatments to improve outcomes for cancer patients.

Step Pharma

This company develops selective CTPS1 inhibitors to treat patients with blood cancers, solid tumours and autoimmune diseases.

iOnctura

The company develops precision small-molecule medicines to treat patients with neglected and hard-to-treat solid tumours and cancers.